Acadia Pharmaceuticals (ACAD) Depreciation & Amortization (CF) (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Depreciation & Amortization (CF) of $271000.0 for Q1 2026, up 18.34% year-over-year from $229000.0 in Q1 2025, and up 17.32% quarter-over-quarter from $231000.0 in Q4 2025.
Acadia Pharmaceuticals (ACAD) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $271000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 18.34% year-over-year to $271000.0; the TTM figure through Mar 2026 stood at $942000.0 (up 6.2% YoY), while the FY2025 annual figure was $900000.0, changed 0.0% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $271000.0, up from $231000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $516000.0 in Q1 2022, with the low at $206000.0 in Q4 2024.
- The 5-year median for Depreciation & Amortization (CF) is $271000.0 (2026), against an average of $325294.1.
- The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) slumped 43.78% in 2024, then grew 18.34% in 2026.
- Acadia Pharmaceuticals' Depreciation & Amortization (CF) stood at $463000.0 in 2022, then tumbled by 41.25% to $272000.0 in 2023, then declined by 24.26% to $206000.0 in 2024, then rose by 12.14% to $231000.0 in 2025, then climbed by 17.32% to $271000.0 in 2026.
- Business Quant data shows ACAD's Depreciation & Amortization (CF) at $271000.0 in Q1 2026, $231000.0 in Q4 2025, and $227000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 434,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 434,000.00 |
| Jun 30, 2026 | 434,000.00 |
| Mar 31, 2026 | 271,000.00 |
| Mar 31, 2026 | 271,000.00 |
| Dec 31, 2025 | 231,000.00 |
| Dec 31, 2025 | 231,000.00 |
| Sep 30, 2025 | 227,000.00 |
| Sep 30, 2025 | 227,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Dec 31, 2024 | 206,000.00 |
| Dec 31, 2024 | 206,000.00 |
| Sep 30, 2024 | 226,000.00 |
| Sep 30, 2024 | 226,000.00 |
| Jun 30, 2024 | 226,000.00 |
| Jun 30, 2024 | 226,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Mar 31, 2024 | 242,000.00 |